Phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible or who refuse cisplatin-based chemotherapy: The PRISMA-1 study.

Details

Language :

English

ISSN :

0732183X

Volume :

43

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

183113436

Full Text :

https://doi.org/10.1200/JCO.2025.43.5_suppl.TPS884